Alan H. Bryce MDChair, Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic; Associate Professor of Medicine, Mayo Clinic College of Medicine and Science, Phoenix, Arizona
Alan H. Bryce, MD, is a consultant in the Division of Hematology and Oncology, Department of Internal Medicine at Mayo Clinic in Arizona and serves as chair of the division. He is also chair of the Genitourinary Disease Group. He holds the academic rank of associate professor of medicine, Mayo Clinic College of Medicine. He joined the staff of Mayo Clinic in 2011.
Dr. Bryce earned his B.S. degree in biochemistry at the University of California, Los Angeles, and his MD degree at Finch University of Health Sciences, Chicago Medical School. He completed a residency in internal medicine and a fellowship and chief fellowship in hematology/oncology at Mayo Graduate School of Medicine.
Dr. Bryce's primary focus in on prostate cancer and testicular cancer. His research centers on developing new approaches to the treatment and cure of cancer. This includes developing new treatments through clinical trials and better understanding of cancer evolution through interrogation of the genetic mutations of individual cancer cells. His work includes studies of immunotherapy, genetically targeted therapies, hormone therapy, injectable radiotherapy, and chemotherapy. Dr. Bryce is committed to health equity and patient centered care. He believes that individualized medicine starts with tailoring all treatment to the patient’s goals and values.
Recent Contributions to PracticeUpdate:
- 2021 Top Story in Prostate Cancer: An Inflection Point — The Dawn of PSMA Theranostics
- ESMO 2021: Recommendations From Dr. Alan Bryce for Prostate and Bladder Cancer
- ASCO 2021: Abstract Recommendations From Dr. Alan Bryce for Prostate Cancer
- Response to Olaparib Among Men With BRCA 1 / 2 or ATM Mutated Prostate Cancer
- Therapeutic Outcomes in CDK12-Altered Prostate Cancer